Eledon Pharmaceuticals (ELDN) Profit After Tax (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Profit After Tax data on file, last reported at -$39.0 million in Q1 2026.

• Quarterly Profit After Tax fell 550.0% year-over-year to -$39.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$76.8 million (down 313.82% YoY) and the FY2025 annual result came in at -$45.6 million, down 26.02% from the prior year.
• Profit After Tax declined to -$39.0 million in Q1 2026, from -$10.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $77.0 million in Q3 2024 to a low of -$65.8 million in Q2 2023.
• A 5-year average of -$19.0 million and a median of -$11.2 million in 2025 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax slumped 611.15% — and 2024, when it soared 877.01%.
• Tracing ELDN's Profit After Tax over 5 years: stood at -$58.4 million in 2022, then surged by 48.45% to -$30.1 million in 2023, then slumped by 48.23% to -$44.6 million in 2024, then surged by 76.62% to -$10.4 million in 2025, then tumbled by 273.92% to -$39.0 million in 2026.
• The last three Profit After Tax figures came in at -$39.0 million (Q1 2026), -$10.4 million (Q4 2025), and -$16.1 million (Q3 2025), per Business Quant data.